Android app on Google Play

Nomura Securities Upgrades Novo Nordisk (NVO) to Buy Post CRL Sell-Off

February 12, 2013 8:04 AM EST Send to a Friend
Get Alerts NVO Hot Sheet
Price: $48.47 --0%

Rating Summary:
    7 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 6 | New: 22
Trade NVO Now!
Join SI Premium – FREE
Nomura Securities upgraded Novo Nordisk (NYSE: NVO) from Neutral to Buy, which follows Monday's 14 percent sell-off after the company received a CRL from the FDA regarding the NDA for Tresiba and Ryzodeg.

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $165.40 yesterday.




You May Also Be Interested In


Related Categories

Hot Upgrades, Upgrades

Related Entities

Nomura

Add Your Comment